When researchers began reexcavating a Viking burial mound in Norway, they knew they were following the footsteps of an influential archaeologist. What they didn’t know was that he’d left them a note ...

Following an end-of-Phase II meeting with the FDA in the fourth quarter, Viking Therapeutics plans to push its subcutaneous obesity therapy VK2735 into late-stage development and to start a Phase II ...

Viking Therapeutics VKTX is set to report third-quarter earnings on Oct. 23, after market close. Since the company lacks a marketed drug in its portfolio, we do not expect it to record revenues ...